Amicus Therapeutics, Inc. (LON:0HF9)

Market Cap	2.18B
Revenue (ttm)	421.99M
Net Income (ttm)	-44.82M
Shares Out	n/a
EPS (ttm)	-0.15
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,497
Average Volume	829
Open	9.15
Previous Close	9.27
Day's Range	9.06 - 9.39
52-Week Range	9.13 - 14.57
Beta	n/a
RSI	39.73
Earnings Date	Feb 27, 2025

About Amicus Therapeutics

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and Glaxo...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 2002
• Employees: 517
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0HF9

Financial Performance

In 2023, Amicus Therapeutics's revenue was $399.36 million, an increase of 21.30% compared to the previous year's $329.23 million. Losses were -$151.58 million, -35.92% less than in 2022.

Financial numbers in USD